Neuland Laboratories growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+37.0%−5.2%+30.8%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+77.7%−30.1%+70.2%
+87.3%−36.0%+83.9%
+39.9%−13.3%+83.5%
+39.9%−13.3%+83.5%
+34.4%+19.0%+16.0%
+22.9%+18.9%+29.0%
+9.2%+21.5%+10.1%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

NEULANDLAB₹18,695.00

Neuland Laboratories Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABLAURUSLABSNHNATCOPHARMLALPATHLABSAILIFECOHANCEASTERDMMcap ₹24,117 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+30.8-5.2+37.0—
EBITDA Growth—+70.2-30.1+77.7—
EBIT Growth—+83.9-36.0+87.3—
Net Income Growth—+83.5-13.3+39.9—
EPS Growth—+83.5-13.3+39.9—
Total Assets Growth—+16.0+19.0+34.4—
Total Equity Growth—+29.0+18.9+22.9—
Cash from Operations Growth—+10.1+21.5+9.2—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.